摘要
Abstract
Objective:To investigate the effect of sitagliptin combined with metformin in the treatment of early macroangiopathy in patients with type 2 diabetes.Methods:A total of 80 patients with early type 2 diabetes with macrovascular disease admitted to Liangzhou Hospital,Wuwei City,Gansu Province from January 2023 to December 2023 were randomly divided into the control group and the study group,with 40 cases in each group.The control group received metformin standardized treatment,and the study group received sitagliptin combined with metformin standardized treatment.Blood glucose indexes,serum cystatin C,homocysteine,C-reactive protein,and the incidence of adverse reactions were compared between the two groups.Results:The fasting blood glucose,2h postprandial blood glucose and HBA1c values of the study group were significantly lower than those of the control group(P<0.05).After treatment,the levels of cystatin C,homocysteine and C-reactive protein in the study group were significantly lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between groups(P>0.05).Conclusion:Sitagliptin combined with metformin is effective in the treatment of early macroangiopathy in patients with type 2 diabetes.关键词
2型糖尿病/大血管病变/西格列汀/二甲双胍/标准化治疗Key words
type 2 diabetes/macroangiopathy/sitagliptin/metformin/standardized treatment
